Screening genetických abnormalit u glioblastomu s využitím komparativní genomové hybridizace s vyšším rozlišením

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F07%3A00021808" target="_blank" >RIV/00216224:14310/07:00021808 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization

Popis výsledku v původním jazyce

Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows genome-wide analysis of DNA sequence copy number differences. We have applied conventional CGH and recently developed high resolution CGH (HR-CGH) to tumour samplesfrom 18 patients with glioblastoma multiforme (GBM) to compare the sensitivity of CGH and HR-CGH in the screening of chromosomal abnormalities. The abnormalities were studied in topologically different central and peripheral tumour parts. A total of 78 different changes were observed using CGH (0-16 per tumour, median 3.5) and 154 different changes using HR-CGH (0-21 per tumour, median 6). Using HR-CGH, losses were more frequent than gains. The representation of the most prominent changes revealed by both methods was similar and was comprised of the amplification of 7q12-13 and 12q12-q15, the gain of 7, 3q and 19 and the loss of 10, 9p, and 13q. However, HR-CGH detected a few other abnormalities (loss of 6, 14q, 15q, and 18q and gain of

Název v anglickém jazyce

Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization

Popis výsledku anglicky

Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows genome-wide analysis of DNA sequence copy number differences. We have applied conventional CGH and recently developed high resolution CGH (HR-CGH) to tumour samplesfrom 18 patients with glioblastoma multiforme (GBM) to compare the sensitivity of CGH and HR-CGH in the screening of chromosomal abnormalities. The abnormalities were studied in topologically different central and peripheral tumour parts. A total of 78 different changes were observed using CGH (0-16 per tumour, median 3.5) and 154 different changes using HR-CGH (0-21 per tumour, median 6). Using HR-CGH, losses were more frequent than gains. The representation of the most prominent changes revealed by both methods was similar and was comprised of the amplification of 7q12-13 and 12q12-q15, the gain of 7, 3q and 19 and the loss of 10, 9p, and 13q. However, HR-CGH detected a few other abnormalities (loss of 6, 14q, 15q, and 18q and gain of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/OC%20B19.001" target="_blank" >OC B19.001: Genová diagnostika a terapie multiformního glioblastomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology Reports

ISSN

1021-335X

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

457-464

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—